Skip to main content

A phase II study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration- resistant prostate cancer (CRPC): A PCCTC trial

Publication ,  Conference
Antonarakis, ES; Heath, EI; Posadas, EM; Harrison, MR; Bruce, JY; Yu, EY; Cho, SY; Wilding, GE; Fetterly, GJ; Hangauer, DG; Kwan, M-FR ...
Published in: JOURNAL OF CLINICAL ONCOLOGY
May 20, 2012

Duke Scholars

Published In

JOURNAL OF CLINICAL ONCOLOGY

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2012

Volume

30

Issue

15

Location

Chicago, IL

Publisher

AMER SOC CLINICAL ONCOLOGY

Conference Name

48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Antonarakis, E. S., Heath, E. I., Posadas, E. M., Harrison, M. R., Bruce, J. Y., Yu, E. Y., … Carducci, M. A. (2012). A phase II study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration- resistant prostate cancer (CRPC): A PCCTC trial. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 30). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
Antonarakis, Emmanuel S., Elisabeth I. Heath, Edwin M. Posadas, Michael Roger Harrison, Justine Yang Bruce, Evan Y. Yu, Steve Y. Cho, et al. “A phase II study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration- resistant prostate cancer (CRPC): A PCCTC trial.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 30. AMER SOC CLINICAL ONCOLOGY, 2012.
Antonarakis ES, Heath EI, Posadas EM, Harrison MR, Bruce JY, Yu EY, et al. A phase II study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration- resistant prostate cancer (CRPC): A PCCTC trial. In: JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2012.
Antonarakis, Emmanuel S., et al. “A phase II study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration- resistant prostate cancer (CRPC): A PCCTC trial.” JOURNAL OF CLINICAL ONCOLOGY, vol. 30, no. 15, AMER SOC CLINICAL ONCOLOGY, 2012.
Antonarakis ES, Heath EI, Posadas EM, Harrison MR, Bruce JY, Yu EY, Cho SY, Wilding GE, Fetterly GJ, Hangauer DG, Kwan M-FR, Dyster LM, Carducci MA. A phase II study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration- resistant prostate cancer (CRPC): A PCCTC trial. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2012.

Published In

JOURNAL OF CLINICAL ONCOLOGY

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2012

Volume

30

Issue

15

Location

Chicago, IL

Publisher

AMER SOC CLINICAL ONCOLOGY

Conference Name

48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences